Vivienne Y. Zhou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Vivienne Y. Zhou has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
Diane Lacaille
Arthritis Research Canada , Vancouver, British Columbia, Canada
2 shared publications- Hui Xie
Arthritis Research Canada, Vancouver, Canada
2 shared publications Jacek A Kopec
Arthritis Research Canada , Vancouver, British Columbia, Canada
2 shared publicationsJohn M Esdaile
Arthritis Research Canada , Vancouver, British Columbia, Canada
2 shared publicationsNa Lu
Arthritis Research Canada , Vancouver, British Columbia, Canada
2 shared publicationsYi Qian
Sauder School of Business, University of British Columbia , Vancouver, British Columbia, Canada
2 shared publications
Latest Publications
- Open Access
Real‐world comparative effects of slow‐release oral morphine vs. methadone on healthcare use for opioid use disorder: A population‐based target trial emulation
Aims: To examine the comparative effects of slow‐release oral morphine (SROM) vs. methadone for the treatment of opioid use disorder (OUD) on healthcare use. Design: This retrospective cohort study emulated a target trial using electronic medical record data from Vancouver Coastal Health Authority linked with population‐based administrative health data from British Columbia (BC), Canada. Setting: Vancouver Coastal Health region in BC, between 1 July 2017 and 30 June 2024, operating under a universal healthcare system, where the majority of illicit opioids are contaminated with fentanyl. Participants: OUD patients aged between 18 and 65 years. Interventions: Intent‐to‐treat (ITT): receiving a new prescription of SROM or methadone for the treatment of OUD (regardless of treatment initiation or adherence). Per‐protocol (PP): initiating and adhering to the prescribed SROM vs methadone (real‐world on‐treatment exposure). Measurements: The daily rate of healthcare use—including all‐cause and opioid‐specific emergency department (ED) visits, all‐cause and opioid‐specific hospitalization days, all‐cause physician encounters/services, OUD‐related physician visits, and non‐OUD‐related primary care physician visits—over 1 year following treatment prescription or initiation was modelled using weighted modified Poisson regression with generalized estimating equations. Cumulative healthcare use at 1 year and corresponding adjusted rate ratios (aRRs) were estimated. Findings: We identified 3254 unique individuals [median (Q1–Q3) age 37 (30–46) years, 64.2% male] contributing to 4059 person‐trials (eligible treatment episodes) for the ITT analysis (32.6% SROM) and 1992 unique individuals contributing to 2276 person‐trials for the PP analysis (27.4% SROM). ITT analysis shows that receiving a SROM vs. methadone prescription was not associated with statistically significant differences in the rates of all‐cause [aRR = 1.10, 95% confidence interval (CI) = 0.997–1.20] and opioid‐specific ED visits (aRR = 1.00, 95% CI = 0.90–1.13), all‐cause (aRR = 0.99, 95% CI = 0.81–1.18) and opioid‐specific hospitalization days (aRR = 0.97, 95% CI = 0.78–1.20), all‐cause physician encounters/services (aRR = 1.00, 95% CI = 0.94–1.06), OUD‐related physician visits (aRR = 0.94, 95% CI = 0.87–1.01) and primary care physician visits (aRR = 1.11, 95% CI = 0.98–1.24). PP analysis also did not observe statistically significant differences across healthcare outcomes among those who initiated and remained on SROM vs. methadone treatment, with aRRs of 1.24 (95% CI = 0.91–1.50), 1.01 (95% CI = 0.67–1.36), 1.06 (95% CI = 0.65–1.58), 0.95 (95% CI = 0.53–1.58), 1.03 (95% CI = 0.90–1.17), 0.97 (95% CI = 0.82–1.14) and 1.06 (95% CI = 0.73–1.46), respectively. Conclusions: This emulated trial on opioid use disorder patients under a universal healthcare setting in Canada did not observe statistically significant differences in risk of healthcare use outcomes between the patients receiving slow‐release oral morphine and those receiving methadone following treatment prescription and initiation. This supports slow‐release oral morphine as a viable alternative to methadone with similar real‐world effectiveness in preventing all‐cause and opioid‐related acute healthcare needs and the potential to expand treatment options for opioid use disorder without increasing health system burden.
Open AccessReal‐world comparative effects of slow‐release oral morphine vs. methadone on healthcare use for opioid use disorder: A population‐based target trial emulation
Aims: To examine the comparative effects of slow‐release oral morphine (SROM) vs. methadone for the treatment of opioid use disorder (OUD) on healthcare use. Design: This retrospective cohort study emulated a target trial using electronic medical record data from Vancouver Coastal Health Authority linked with population‐based administrative health data from British Columbia (BC), Canada. Setting: Vancouver Coastal Health region in BC, between 1 July 2017 and 30 June 2024, operating under a universal healthcare system, where the majority of illicit opioids are contaminated with fentanyl. Participants: OUD patients aged between 18 and 65 years. Interventions: Intent‐to‐treat (ITT): receiving a new prescription of SROM or methadone for the treatment of OUD (regardless of treatment initiation or adherence). Per‐protocol (PP): initiating and adhering to the prescribed SROM vs methadone (real‐world on‐treatment exposure). Measurements: The daily rate of healthcare use—including all‐cause and opioid‐specific emergency department (ED) visits, all‐cause and opioid‐specific hospitalization days, all‐cause physician encounters/services, OUD‐related physician visits, and non‐OUD‐related primary care physician visits—over 1 year following treatment prescription or initiation was modelled using weighted modified Poisson regression with generalized estimating equations. Cumulative healthcare use at 1 year and corresponding adjusted rate ratios (aRRs) were estimated. Findings: We identified 3254 unique individuals [median (Q1–Q3) age 37 (30–46) years, 64.2% male] contributing to 4059 person‐trials (eligible treatment episodes) for the ITT analysis (32.6% SROM) and 1992 unique individuals contributing to 2276 person‐trials for the PP analysis (27.4% SROM). ITT analysis shows that receiving a SROM vs. methadone prescription was not associated with statistically significant differences in the rates of all‐cause [aRR = 1.10, 95% confidence interval (CI) = 0.997–1.20] and opioid‐specific ED visits (aRR = 1.00, 95% CI = 0.90–1.13), all‐cause (aRR = 0.99, 95% CI = 0.81–1.18) and opioid‐specific hospitalization days (aRR = 0.97, 95% CI = 0.78–1.20), all‐cause physician encounters/services (aRR = 1.00, 95% CI = 0.94–1.06), OUD‐related physician visits (aRR = 0.94, 95% CI = 0.87–1.01) and primary care physician visits (aRR = 1.11, 95% CI = 0.98–1.24). PP analysis also did not observe statistically significant differences across healthcare outcomes among those who initiated and remained on SROM vs. methadone treatment, with aRRs of 1.24 (95% CI = 0.91–1.50), 1.01 (95% CI = 0.67–1.36), 1.06 (95% CI = 0.65–1.58), 0.95 (95% CI = 0.53–1.58), 1.03 (95% CI = 0.90–1.17), 0.97 (95% CI = 0.82–1.14) and 1.06 (95% CI = 0.73–1.46), respectively. Conclusions: This emulated trial on opioid use disorder patients under a universal healthcare setting in Canada did not observe statistically significant differences in risk of healthcare use outcomes between the patients receiving slow‐release oral morphine and those receiving methadone following treatment prescription and initiation. This supports slow‐release oral morphine as a viable alternative to methadone with similar real‐world effectiveness in preventing all‐cause and opioid‐related acute healthcare needs and the potential to expand treatment options for opioid use disorder without increasing health system burden.
- 4 April 2023
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 62 (12) , 3858-3865
Risk of severe infections after the introduction of biologic DMARDs in people with newly diagnosed rheumatoid arthritis: a population-based interrupted time-series analysis
Objectives: To determine the impact of the introduction of biologic DMARDs (bDMARDs) on severe infections among people newly diagnosed with RA compared with non-RA individuals. Methods: In this population-based retrospective cohort study using administrative data (from 1990–2015) for British Columbia, Canada, all incident RA patients diagnosed between 1995 and 2007 were identified. General population controls with no inflammatory arthritis were matched to RA patients based on age and gender, and were assigned the diagnosis date (i.e. index date) of the RA patients they were matched with. RA/controls were then divided into quarterly cohorts according to their index dates. The outcome of interest was all severe infections necessitating hospitalization or occurring during hospitalization after the index date. We calculated 8-year severe infection rates for each cohort and conducted interrupted time-series analyses to compare severe infection trends in RA/controls with index date during pre-bDMARDs (1995–2001) and post-bDMARDs (2003–2007) periods. Results: A total of 60 226 and 588 499 incident RA/controls were identified. We identified 14 245 severe infections in RA, and 79 819 severe infections in controls. The 8-year severe infection rates decreased among RA/controls with increasing calendar year of index date in the pre-bDMARDs period, but increased over time only among RA, not controls, with index date in the post-bDMARDs period. The adjusted difference between the pre- and post-bDMARDs secular trends in 8-year severe infection rates was 1.85 (P = 0.001) in RA and 0.12 (P = 0.29) in non-RA. Conclusion: RA onset after bDMARDs introduction was associated with an elevated severe infection risk in RA patients compared with matched non-RA individuals.
- 4 April 2023
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 62 (12) , 3858-3865
Risk of severe infections after the introduction of biologic DMARDs in people with newly diagnosed rheumatoid arthritis: a population-based interrupted time-series analysis
Objectives: To determine the impact of the introduction of biologic DMARDs (bDMARDs) on severe infections among people newly diagnosed with RA compared with non-RA individuals. Methods: In this population-based retrospective cohort study using administrative data (from 1990–2015) for British Columbia, Canada, all incident RA patients diagnosed between 1995 and 2007 were identified. General population controls with no inflammatory arthritis were matched to RA patients based on age and gender, and were assigned the diagnosis date (i.e. index date) of the RA patients they were matched with. RA/controls were then divided into quarterly cohorts according to their index dates. The outcome of interest was all severe infections necessitating hospitalization or occurring during hospitalization after the index date. We calculated 8-year severe infection rates for each cohort and conducted interrupted time-series analyses to compare severe infection trends in RA/controls with index date during pre-bDMARDs (1995–2001) and post-bDMARDs (2003–2007) periods. Results: A total of 60 226 and 588 499 incident RA/controls were identified. We identified 14 245 severe infections in RA, and 79 819 severe infections in controls. The 8-year severe infection rates decreased among RA/controls with increasing calendar year of index date in the pre-bDMARDs period, but increased over time only among RA, not controls, with index date in the post-bDMARDs period. The adjusted difference between the pre- and post-bDMARDs secular trends in 8-year severe infection rates was 1.85 (P = 0.001) in RA and 0.12 (P = 0.29) in non-RA. Conclusion: RA onset after bDMARDs introduction was associated with an elevated severe infection risk in RA patients compared with matched non-RA individuals.
- 9 August 2021
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 61 (5) , 1819-1830
Has the incidence of total joint arthroplasty in rheumatoid arthritis decreased in the era of biologics use? A population-based cohort study
To determine whether the introduction of biological DMARDs (bDMARDs) was associated with reduced incidences of total hip and knee arthroplasty (THA/TKA) among patients with RA compared with OA. Using a population-based cohort in British Columbia, Canada, RA and OA patients diagnosed between 1995 and 2007 were divided into semi-annual cohorts according to diagnosis date. For each cohort, we calculated 8-year incidence rates of THA and TKA. We compared levels and trends of THA/TKA incidence in RA/OA patients diagnosed during pre-bDMARDs (1995–2001) and post-bDMARDs (2003–2007) periods using interrupted time-series analysis, adjusting for baseline characteristics. Adjusted 8-year total joint arthroplasty incidence estimated for RA/OA cohorts diagnosed five years after bDMARDs introduction were compared with expected rates assuming no bDMARDs introduction, based on extrapolation of pre-bDMARDs trends. We identified 60 227 RA and 288 260 OA incident cases. For cohorts diagnosed pre-bDMARDs, 8-year THA/TKA incidence rates increased over time in both RA and OA. For cohorts diagnosed post-bDMARDs, these rates decreased over time in RA but continued to increase for OA. For RA, differences between the post- and pre-bDMARDs secular trends in incidence rates were −0.49 (P = 0.002) for THA and −0.36 (P = 0.003) for TKA, compared with +0.40 (P = 0.006) and +0.54 (P < 0.001), respectively, for OA. For RA cohorts diagnosed five years after bDMARDs introduction, 8-year incidences were 26.9% and 12.6% lower for THA and TKA, respectively, than expected rates. In contrast, corresponding rates in OA were higher by 11.7% and 16.6%, respectively. Arthritis onset after bDMARDs introduction is associated with a significant reduction in THA/TKA incidence in RA, but not in OA. The reduction reflects a significant improvement in RA treatment during the biological era.
- 9 August 2021
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 61 (5) , 1819-1830
Has the incidence of total joint arthroplasty in rheumatoid arthritis decreased in the era of biologics use? A population-based cohort study
To determine whether the introduction of biological DMARDs (bDMARDs) was associated with reduced incidences of total hip and knee arthroplasty (THA/TKA) among patients with RA compared with OA. Using a population-based cohort in British Columbia, Canada, RA and OA patients diagnosed between 1995 and 2007 were divided into semi-annual cohorts according to diagnosis date. For each cohort, we calculated 8-year incidence rates of THA and TKA. We compared levels and trends of THA/TKA incidence in RA/OA patients diagnosed during pre-bDMARDs (1995–2001) and post-bDMARDs (2003–2007) periods using interrupted time-series analysis, adjusting for baseline characteristics. Adjusted 8-year total joint arthroplasty incidence estimated for RA/OA cohorts diagnosed five years after bDMARDs introduction were compared with expected rates assuming no bDMARDs introduction, based on extrapolation of pre-bDMARDs trends. We identified 60 227 RA and 288 260 OA incident cases. For cohorts diagnosed pre-bDMARDs, 8-year THA/TKA incidence rates increased over time in both RA and OA. For cohorts diagnosed post-bDMARDs, these rates decreased over time in RA but continued to increase for OA. For RA, differences between the post- and pre-bDMARDs secular trends in incidence rates were −0.49 (P = 0.002) for THA and −0.36 (P = 0.003) for TKA, compared with +0.40 (P = 0.006) and +0.54 (P < 0.001), respectively, for OA. For RA cohorts diagnosed five years after bDMARDs introduction, 8-year incidences were 26.9% and 12.6% lower for THA and TKA, respectively, than expected rates. In contrast, corresponding rates in OA were higher by 11.7% and 16.6%, respectively. Arthritis onset after bDMARDs introduction is associated with a significant reduction in THA/TKA incidence in RA, but not in OA. The reduction reflects a significant improvement in RA treatment during the biological era.